Zynerba is developing transdermal cannabis drugs and prodrugs for the treatment of Fragile X syndrome, autism spectrum disorder, developmental and epileptic encephalopathies, and 22q. As of July 2021, its patented Zygel™ topical CBD gel has not been approved by government agencies in the US.
| Loading Documents... |
